Newsbenzinga
TG Therapeutics Says BRIUMVI Showed 44% Lower Risk Of MS Disability Progression vs. Ocrelizumab, 49% vs. Ofatumumab In Indirect Comparison
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…